Literature DB >> 11112213

Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.

R P Perez1, P Zhang, A K Bosserhoff, R Buettner, M Abu-Hadid.   

Abstract

Melanoma inhibitory activity (MIA) is a small soluble protein secreted by malignant melanoma cells and chondrocytes. Prior studies suggested that MIA expression was relatively tissue-specific, making it a potentially useful marker for melanoma. The current investigations sought to more clearly define the range of tumor/tissue-types where MIA is expressed, compared with expression of 4 other potential melanoma marker genes (tyrosinase melanoma antigen recognized by T cells [MART-1/MelanA], gp100, and melanoma growth-stimulatory activity [MGSA/Gro alpha]). Expression of these genes was assayed by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry in 23 melanoma tumor specimens and in 25 additional nonmelanoma or nonmalignant specimens. MIA, tyrosinase, and MGSA were expressed in most melanoma specimens. Specificity was highest for MART-1, followed by MIA and tyrosinase. Increasing the number of cycles of amplification from 35 to 40 increased sensitivity but decreased specificity of most markers, though MIA was relatively robust. MIA mRNA was also detected in carcinomas of the colon, ovary, kidney, and head/neck, as well as in normal laryngeal epithelium. Although MIA discriminated melanoma from nonmelanoma at least as well as tyrosinase, no single mRNA marker had accuracy greater than 71%, raising potential concern about application of these particular mRNA markers to the minimal disease setting. HUM PATHOL 31:1381-1388. Copyright 2000 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112213

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity.

Authors:  Saskia A Graf; Christian Busch; Anja-Katrin Bosserhoff; Robert Besch; Carola Berking
Journal:  J Invest Dermatol       Date:  2014-03-07       Impact factor: 8.551

2.  [Serum markers for melanoma].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

Review 3.  Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.

Authors:  Kendra C Foley; Michael I Nishimura; Tamson V Moore
Journal:  Melanoma Res       Date:  2018-06       Impact factor: 3.599

4.  Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype.

Authors:  Ina Poser; Michaela Golob; Reinhard Buettner; Anja K Bosserhoff
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

5.  Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.

Authors:  Markus Essler; Anna Link; Benedetta Belloni; Vesna Mirceva; Michael Souvatzoglou; Markus Thaler; Bernhard Haller; Ruediger Hein; Bernd J Krause
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

6.  Promoters with cancer cell-specific activity for melanoma gene therapy.

Authors:  V V Pleshkan; I V Alekseenko; M V Zinovyeva; T V Vinogradova; E D Sverdlov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.